NCT01733758 - A Monotherapy Study to Evaluate the Efficacy and Safety of 2 Dose Levels of Albiglutide in Japanese Subjects With Type 2 Diabetes Mellitus (T2DM) | Biotech Hunter

Enrollment

494

Participants

Timeline

Start Date

February 28, 2013

Primary Completion Date

June 30, 2014

Study Completion Date

February 28, 2015

Conditions

Diabetes Mellitus, Type 2

Interventions

DRUG

Albiglutide 30 mg weekly

Albiglutide will be available as a pen injector that delivers 30mg of albiglutide

DRUG

Albiglutide 50 mg weekly

Albiglutide will be available as a pen injector that delivers 50mg of albiglutide

DRUG

Placebo

Albiglutide matching placebo will be available as a pen injector

DRUG

Liraglutide 0.9 mg daily

Liraglutide will be available as prefilled multidose pens that can deliver 0.9 mg dose

Trial Locations (74)

456-0058

GSK Investigational Site, Aichi

263-0043

GSK Investigational Site, Chiba

790-0067

GSK Investigational Site, Ehime

792-0045

GSK Investigational Site, Ehime

792-8586

GSK Investigational Site, Ehime

810-0014

GSK Investigational Site, Fukuoka

812-0053

GSK Investigational Site, Fukuoka

815-8588

GSK Investigational Site, Fukuoka

819-0168

GSK Investigational Site, Fukuoka

960-0418

GSK Investigational Site, Fukushima

961-0416

GSK Investigational Site, Fukushima

963-8851

GSK Investigational Site, Fukushima

964-8501

GSK Investigational Site, Fukushima

370-3573

GSK Investigational Site, Gunma

379-0116

GSK Investigational Site, Gunma

731-0103

GSK Investigational Site, Hiroshima

040-8585

GSK Investigational Site, Hokkaido

062-0007

GSK Investigational Site, Hokkaido

070-0002

GSK Investigational Site, Hokkaido

072-0012

GSK Investigational Site, Hokkaido

080-0010

GSK Investigational Site, Hokkaido

080-0016

GSK Investigational Site, Hokkaido

670-0074

GSK Investigational Site, Hyōgo

300-0835

GSK Investigational Site, Ibaraki

300-1512

GSK Investigational Site, Ibaraki

311-0113

GSK Investigational Site, Ibaraki

760-0017

GSK Investigational Site, Kagawa

760-0076

GSK Investigational Site, Kagawa

890-0061

GSK Investigational Site, Kagoshima

212-0024

GSK Investigational Site, Kanagawa

232-0064

GSK Investigational Site, Kanagawa

235-0045

GSK Investigational Site, Kanagawa

238-0011

GSK Investigational Site, Kanagawa

242-0004

GSK Investigational Site, Kanagawa

253-0044

GSK Investigational Site, Kanagawa

780-0088

GSK Investigational Site, Kochi

862-0976

GSK Investigational Site, Kumamoto

866-8660

GSK Investigational Site, Kumamoto

867-0041

GSK Investigational Site, Kumamoto

600-8558

GSK Investigational Site, Kyoto

601-1495

GSK Investigational Site, Kyoto

980-0021

GSK Investigational Site, Miyagi

985-0852

GSK Investigational Site, Miyagi

385-0022

GSK Investigational Site, Nagano

399-0006

GSK Investigational Site, Nagano

399-0036

GSK Investigational Site, Nagano

634-0007

GSK Investigational Site, Nara

901-0243

GSK Investigational Site, Okinawa

530-0001

GSK Investigational Site, Osaka

530-0004

GSK Investigational Site, Osaka

530-0012

GSK Investigational Site, Osaka

532-0026

GSK Investigational Site, Osaka

536-0023

GSK Investigational Site, Osaka

538-0044

GSK Investigational Site, Osaka

577-0803

GSK Investigational Site, Osaka

870-0039

GSK Investigational Site, Ōita

876-0851

GSK Investigational Site, Ōita

332-0012

GSK Investigational Site, Saitama

350-0035

GSK Investigational Site, Saitama

350-0851

GSK Investigational Site, Saitama

354-0031

GSK Investigational Site, Saitama

355-0321

GSK Investigational Site, Saitama

358-0011

GSK Investigational Site, Saitama

424-0855

GSK Investigational Site, Shizuoka